Supernus Capital Expenditures from 2010 to 2024

SUPN Stock  USD 29.24  0.24  0.83%   
Supernus Pharmaceuticals Capital Expenditures yearly trend continues to be very stable with very little volatility. Capital Expenditures is likely to drop to about 523.5 K. During the period from 2010 to 2024, Supernus Pharmaceuticals Capital Expenditures quarterly data regression pattern had sample variance of 904.9 B and median of  1,062,374. View All Fundamentals
 
Capital Expenditures  
First Reported
2008-12-31
Previous Quarter
150 K
Current Value
36 K
Quarterly Volatility
608.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Supernus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Supernus main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.1 M, Interest Expense of 2.3 M or Total Revenue of 637.9 M, as well as many exotic indicators such as Price To Sales Ratio of 2.47, Dividend Yield of 0.0 or PTB Ratio of 1.51. Supernus financial statements analysis is a perfect complement when working with Supernus Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Supernus Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Supernus Pharmaceuticals Technical models . Check out the analysis of Supernus Pharmaceuticals Correlation against competitors.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

Latest Supernus Pharmaceuticals' Capital Expenditures Growth Pattern

Below is the plot of the Capital Expenditures of Supernus Pharmaceuticals over the last few years. Capital Expenditures are funds used by Supernus Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Supernus Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software. It is Supernus Pharmaceuticals' Capital Expenditures historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Supernus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Capital Expenditures10 Years Trend
Very volatile
   Capital Expenditures   
       Timeline  

Supernus Capital Expenditures Regression Statistics

Arithmetic Mean1,449,388
Geometric Mean1,166,828
Coefficient Of Variation65.63
Mean Deviation822,838
Median1,062,374
Standard Deviation951,281
Sample Variance904.9B
Range3M
R-Value0.03
Mean Square Error973.9B
R-Squared0.0007
Significance0.93
Slope5,598
Total Sum of Squares12.7T

Supernus Capital Expenditures History

2024523.5 K
2023551 K
2022412 K
2021M
20203.4 M
20192.7 M
2018844 K

About Supernus Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Supernus Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Supernus Pharmaceuticals investors use historical funamental indicators, such as Supernus Pharmaceuticals's Capital Expenditures, to determine how well the company is positioned to perform in the future. Although Supernus Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Supernus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Supernus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Supernus Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Supernus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Expenditures551 K523.5 K

Currently Active Assets on Macroaxis

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:
Check out the analysis of Supernus Pharmaceuticals Correlation against competitors.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Supernus Stock analysis

When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
0.02
Revenue Per Share
11.14
Quarterly Revenue Growth
(0.02)
Return On Assets
0.0056
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.